TY - JOUR
T1 - Host defense antimicrobial peptides as antibiotics
T2 - design and application strategies
AU - Mishra, Biswajit
AU - Reiling, Scott
AU - Zarena, D.
AU - Wang, Guangshun
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/6/1
Y1 - 2017/6/1
N2 - This review deals with the design and application strategies of new antibiotics based on naturally occurring antimicrobial peptides (AMPs). The initial candidate can be designed based on three-dimensional structure or selected from a library of peptides from natural or laboratory sources followed by optimization via structure-activity relationship studies. There are also advanced application strategies such as induction of AMP expression from host cells by various factors (e.g., metals, amino acids, vitamin D and sunlight), the use of engineered probiotic bacteria to deliver peptides, the design of prodrug and peptide conjugates to improve specific targeting. In addition, combined uses of newly developed AMPs with existing antimicrobial agents may provide a practical avenue for effective management of antibiotic-resistant bacteria (superbugs), including biofilms. Finally, we highlight AMPs already in use or under clinical trials.
AB - This review deals with the design and application strategies of new antibiotics based on naturally occurring antimicrobial peptides (AMPs). The initial candidate can be designed based on three-dimensional structure or selected from a library of peptides from natural or laboratory sources followed by optimization via structure-activity relationship studies. There are also advanced application strategies such as induction of AMP expression from host cells by various factors (e.g., metals, amino acids, vitamin D and sunlight), the use of engineered probiotic bacteria to deliver peptides, the design of prodrug and peptide conjugates to improve specific targeting. In addition, combined uses of newly developed AMPs with existing antimicrobial agents may provide a practical avenue for effective management of antibiotic-resistant bacteria (superbugs), including biofilms. Finally, we highlight AMPs already in use or under clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85017159441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017159441&partnerID=8YFLogxK
U2 - 10.1016/j.cbpa.2017.03.014
DO - 10.1016/j.cbpa.2017.03.014
M3 - Review article
C2 - 28399505
AN - SCOPUS:85017159441
SN - 1367-5931
VL - 38
SP - 87
EP - 96
JO - Current Opinion in Chemical Biology
JF - Current Opinion in Chemical Biology
ER -